echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lilalutide's second indication approved

    Lilalutide's second indication approved

    • Last Update: 2020-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    REVIEW: the only with lower cardiovascular risk indications of hypoglycemic drugsCardiovascular indicationsNovopeptide injection has been approved and is currently the only reduce the risk of cardiovascular indications hypoglycemic drugsliraglutide (liraglutide) is developed by Novo Nordisk a glucagon-like peptide -1 (GLP-1) analogs, has been approved in more than 100 countries, treatment 2 The number of patients with diabetes more than 1.2 millionSince listing, the drug worldwide sales increased year by year, and in 2018 global sales of 28.875 billion yuan, ranked No1 in the world in all hypoglycemic agents2011 Nian liraglutide in the country approved under the trade name Novo force, in July 2017 access to health insurance, its 2018 sales rose 73 percent, reaching 521 million Danish kroner, accounting for the domestic market 87 GLP-1 % market share, the total diabetes market 1.3% market shareDomestic market Liraglutide Novo Nordisk still a monopoly, and successful health care renewal in 2019, with approval expected in the future new indications, liraglutide is expected to usher in further sales of a new highrecent years, the domestic generic pharmaceutical companies have begun to force, Shenzhen Han-woo, are Jianxiang declaration listed four categories of new drugs, nine genes (Huadong Medicine) and Tonghua Dongbao is currently in clinical phase IIIOther domestic East Sunshine medicine, Chinese bio-pharmaceutical, and other domestic manufacturers are also Fosun Pharma layoutEditor: This article is drug Chi Meng Mengcontent network integration, belongs to original author, aimed at passing reproduced more information, do not represent the views of this platformInvolving work content, copyright and other issues, please contact the website message, we will remove content for the first timeRelated Tags:a country, a Novo Nordisk, liraglutide, cardiovascular 0 0
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.